Clinical Pipeline

Below is our pipeline of investigational compounds that are currently in various stages of clinical development.

Phase 1Phase 2Phase 3

Guadecitabine (SGI-110)

DNMT inhibitor (Hematological Malignancies and Solid Tumors)

Guadecitabine (SGI-110)

DNMT inhibitor (Treatment Naïve AML)

...

Guadecitabine (SGI-110)

DNMT inhibitor (Relapsed/Refractory AML)

...

Guadecitabine (SGI-110)

DNMT inhibitor (Relapsed/Refractory MDS or CMML)

...

Guadecitabine (SGI-110)

DNMT inhibitor (Solid Tumors)

. .

ASTX727 (Cedazuridine and Decitabine)

Oral DNMT inhibitor (Hematological Malignancies)

...

ASTX660

Dual IAP Antagonist (Solid Tumors & Lymphomas)

..

ASTX029

Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)

.

ASTX295

Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)

.